News

The primary efficacy endpoint of the studies was defined as a significant change in HbA1c from baseline compared to placebo with empagliflozin 10mg and 25mg once daily doses.

The antacid Rolaids is intended to help relieve heartburn and acid indigestion. Chattem chief executive officer Zan Guerry said, "The addition of Rolaids represents a rare opportunity to

Modified T cells are developed by genetically modifying patient’s own T cells to present the selected transduced T cell receptors (TCR) and then re-infusing the T cells into

NDA filing was based on positive efficacy and safety data demonstrated by several Phase 3 studies conducted in CKD patients with hyperphosphatemia. Keryx chief executive officer Ron Bentsur

The milestone expands the diabetes and beta cell regeneration collaboration until 2013 besides generating a commercial license granted to MedImmune. According to the agreement signed between the companies

The collaboration will leverage RNA modification technology developed by Ethris and its co-founders, Dr. Carsten Rudolph and Prof. Christian Plank, to produce SNIM-RNA molecules ideal for use in

The companies expect to commence Phase 1 study of the AMP-110 immune modulation therapy, which targets autoimmune diseases by blocking inflammatory T cell differentiation, in the first half

The trial will also evaluate the effect of the drug on glucose and insulin resistance. Rhythm chief development officer Liz Stoner said the Phase 2 study is expected

Double-blind trial is being conducted in collaboration with the Friedreich’s Ataxia Research Alliance (FARA) Clinical Research Network and FARA’s Patient Registry. FARA President Ronald Bartek said the organisation